An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease.

ABSTRACT:

Objective

The aim of this study was to preliminarily evaluate an oral small molecule p38α kinase inhibitor in patients with early Alzheimer's disease (AD) for the effects on brain amyloid plaque load and episodic memory function, and to establish pharmacokinetic-pharmacodynamics correlations if any effects identified on these parameters.

Methods

Sixteen patients with early AD received a highly selective p38α inhibitor (neflamapimod) for 84 days (12 weeks). To obtain a broad range of plasma drug exposures, subjects randomized to receive either 40 mg (n = 9) or 125 mg (n = 7) twice daily. Dynamic, ¹¹C-PiB positron emission scans were performed at baseline and at Day 84 and quantitatively analyzed by reference parametric mapping. Episodic

SUBMITTER: Scheltens P 

PROVIDER: S-EPMC5899915 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature